Select a Region North America

Expertise

Jeff LaVaute

Managing Director, Market Access Strategy

Expertise:

Neurology/CNS, Stakeholder Engagement & Promotion (Patients, Payers, Providers)

For more than 20 years, including over 14 years focused on payer decision-making, Jeff has helped clients execute impactful, award-winning campaigns built on an understanding of the audience’s journey and healthcare experience.

He is a firm believer in the IHI Triple Aim, which drives him to find innovative solutions that break down complex science, care patterns, and reimbursement issues so that customers can make informed decisions that will benefit patients, populations, and the quality of care.

His expert understanding of how to promote brands across channels (commercial, Medicare, and Medicaid), sites of care (hospitals, long-term care facilities, and outpatient facilities), and audience (payer, HCP, patient, and advocacy) has allowed Jeff to contribute valuable insights and leadership to clients.

His therapeutic areas of focus include multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, anti-obesity, and several ultra-orphan diseases. Jeff holds an MPH from Columbia University.

Articles by Jeff LaVaute

Telling the Whole Story: An Integrated Approach to Value Proposition Creation

Market shifts are underway, emphasizing the need for value propositions that are more seamless and integrated across functions. Adapting to these changes will be critical if manufacturers want to maximize pricing opportunities and avoid missing opportunities to generate data to demonstrate their product’s value effectively with different audiences. The most robust value propositions require expertise from strategy, clinical, value and evidence, as well as agency execution, but the siloed nature of many manufacturers can make this an operational challenge. By leveraging an integrated, cross-functional approach to value proposition development, manufacturers will gain the ability to define evidence gaps, opening up more opportunities to partner with potential payers in order to […]

How COVID-19 Has Changed Payer Engagement Strategies

The healthcare industry is rightly focused on COVID-19 and its impact on patient care and allocation or utilization of healthcare resources. However, we cannot lose sight of our responsibility to provide appropriate therapeutic options for the over 150 million Americans who suffer from chronic diseases, including the 25-35 million Americans who suffer from rare diseases. As professionals responsible for building content and educating decision makers on various treatment options, we have an important role to play. As we continue to advocate for access to cost-effective care through improved quality and a focus on outcomes, our approach to engaging payers will shift. So what does this all mean for how pharmaceutical […]

Rethinking Patient Centricity in a Dynamic Market Access Driven Ecosystem

Understanding the Complexities and Interdependencies that Deliver Successful Outcomes. As the industry moves to a patient-centric, value-based care model, stakeholders across the continuum of care are focused on creating systems and solutions that put the patient at the forefront of decision making. This requires an alignment of priorities, such as patient engagement, HCP practice efficiency, and supply chain operations to achieve optimal market access and deliver outcomes that matter. While the intent is clear, putting this into practice can be extremely difficult. Gaining and sustaining patient-centric market access requires deep knowledge of the roles that stakeholders play to drive value. A one-sized-fits-all solution will not work because ‘all healthcare is […]

Adopting a Patient-Centric Approach to Ensure Safe and Effective Use

Healthcare leaders often talk about ensuring that the right patient receives the right medication at the right time. On its face, this concept seems straightforward. We know that different patients respond differently to different therapies, such that we cannot consistently replicate randomized clinical trial experience in the real world. Thus, healthcare providers (HCPs) must make their treatment decisions by balancing the need for an efficacious treatment with maintaining safe and effective use of that product. From Jeffrey LaVaute’s point of view, we must engage patients as partners by leveraging digital solutions and by developing interactions that demonstrate an understanding of where patients come from, which factors influence their healthcare decisions, […]

Interested in scheduling a meeting or speaking event?

お問い合わせ